Background: Clinical studies indicate switching to a second biologic or combination therapy with an immunosuppressant after failure of first biologic can be effective in patients with moderate to severe plaque psoriasis not responding to the first biologic.
BACkgRoUnD
• Chronic plaque psoriasis is the most common autoimmune disease in the United States (US), affecting approximately 2.2% of the population. 1 • Several biologics currently are indicated for treatment of psoriasis, including etanercept, adalimumab, infliximab, and ustekinumab.
• Choice of the first-line biologic therapy as well as subsequent treatment in those patients who fail or who are intolerant of the first-line biologic treatment is not yet standardized, and data evaluating treatment-sequencing strategies are generally limited to estimates of efficacy for a biologic in individuals who have already failed treatment with any other biologic. [2] [3] [4] • Health technology assessment (HTA) guidelines lack specific recommendations on best practice for selecting alternative treatment-sequencing strategies.
oBJeCTive
• To assess the extent to which cost-effectiveness models of first-line biologic treatment of moderate to severe plaque psoriasis include subsequent treatment after failure of the first-line biologic.
MeThoDS
• Systematic literature searches were undertaken for two specific topics: 1) cost-effectiveness models for biologic treatments for moderate to severe chronic plaque psoriasis; and 2) treatment guidelines for moderate to severe chronic plaque psoriasis.
• The following electronic databases were searched: MEDLINE, Embase, EconLit, and The Cochrane Library. In addition, conference abstracts were searched from January 2011 to February 2013 in the National Guideline Clearinghouse, National Institute of Clinical Excellence (NICE), Canadian Agency for Drugs and Technologies in Health, German Institute for Quality and Efficiency in Healthcare, Pharmaceutical Benefits Advisory Committee.
• Searches to identify economic analyses, clinical practice guidelines (CPGs), and treatment patterns were conducted from January 1, 1990, to February 20, 2013 . No limitations on publication language or geographic perspective were applied for the economic analysis searches.
• Economic analysis (cost minimization, cost-effectiveness analysis, cost-utility analysis, and cost-benefit analysis) and CPGs, developed using rigorous methodology, were included in this review.
• Cost-of-illness or economic burden studies, subjects with types of psoriasis other than plaque psoriasis, children with psoriasis, case reports, letters, comments, editorials, or reviews were not included in the review.
• For each eligible study, data were extracted and a qualitative synthesis was performed by one researcher and verified with the original sources by a second researcher.
ReSUlTS
• A total of 882 records were retrieved after the searches were performed, and 32 studies were included in the review. Of the included studies, 25 were economic analysis studies and 7 were CPG publications (Figure 1 ). • We identified 25 cost-effectiveness models focusing on biologic therapy for moderate to severe chronic plaque psoriasis.
• All the models included only individuals with chronic plaque psoriasis; all but one model (which only included severe cases) included individuals with moderate or severe disease.
• In 15 of the models reviewed, active treatment after failure of the first-line biologic was not considered.
-In 10 of these 15 models [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , cost-effectiveness was estimated as the cost per responder in a short-term analysis (varying from 12 weeks to 18 months), with discontinuation from the first-line biologic not explicitly considered in the model.
-In the other 5 models, cost-effectiveness was estimated over a 10-year time horizon. In these 5 models, discontinuation from the first-line biologic was assumed to be followed by switch to topical treatment 15 or nonsystemic treatment 16;17 , no further active treatment 18 , or best supportive care. 19 • In 10 of the 25 models reviewed, treatment sequencing with an active treatment after failure of the first-line biologic was explicitly included in the analysis. The time horizons for the cost-effectiveness analyses in these models ranged from 96 weeks to 10 years.
-In only 5 out of these 10 models, were details about the optimal sequencing strategy or the treatment pathways included (Table 1) . The other 5 models were available as abstracts only.
-Three of the five models 22;24;25 were all based on the same model structure (York) originally developed by Woolacott and colleagues. 25 -All three studies estimated the optimal sequencing strategy, none of the studies estimated the net benefits or cost-effectiveness associated with that strategy compared with alternative sequencing strategies. However, Woolacott and colleagues 25 provided an equation for estimating the net benefits for any given sequencing strategy (e.g., A followed by B and then C), assuming that patients who do not achieve Psoriasis Area and Severity Index (PASI) 75 with each treatment nevertheless experience some gain in quality of life while still on the treatment before switching to the next treatment in the pathway:
Net benefits (A, B, C) = NB A + (1 -PA75) × NB B + (1 -PA75) × (1 -PB75) × NB C , where NB A , NB B , and NB C are the net benefits estimated for treatment A, B, and C, respectively PA75 and PB75 = probability of achieving a PASI 75 response or better with treatment A and B, respectively -The other two studies 20;23 that reported the active sequence of biologic treatments in their cost-effectiveness models estimated the cost-effectiveness of different first-line biologic therapies with treatment sequences that included switches to specified second-and third-line treatments after failure of the first-line biologic. [26] [27] [28] and five for Europe. [29] [30] [31] [32] [33] [34] • In the North American guidelines, biologics are indicated for first line therapy and may be used without prior failure on methotrexate or ciclosporin. However, in Europe, biologics are indicated only for patients who have failed nonbiologic systemic therapy, such as methotrexate or ciclosporin, and/or who have failed psoralen plus ultraviolet A.
Author, Year
• Although none of the guidelines recommend any specific biologic for first-line use, some provide guidance for selection of the first-line biologic based on magnitude or rapidity or durability of response. However, the Canadian, German, and NICE guidelines do not provide any guidance for choice of the first-line biologic, although the NICE guidelines require a PASI score of 20 or greater and a DLQI score of 18 or greater in order for infliximab to be used first line.
north America -Recommendations for Treatment Sequencing
• The Canadian guidelines provide no guidance for what to do after failure of the first biologic drug.
• The US guidelines 27;28 state that there is no specific sequencing for biologics but recognize that loss of response may occur after a year on TNF-alpha antagonists, necessitating combination treatment with phototherapy or methotrexate or switching to another biologic. However, the treatment algorithm presented in the most recent US guidelines 28 shows combination therapy as the treatment of choice after failure of first-line systemic monotherapy.
europe -Recommendations for Treatment Sequencing
• The European guidelines 31 do not provide any guidance on what to do after failure of the first biologic drug.
• The Spanish guidelines recommend assessing the response to biologic therapy at weeks 12 through 16 and switching to an alternative treatment regimen if the PASI response is less than 50.
• The UK guidelines 34 suggest that a second TNF-alpha antagonist can be effective after failure of a first-line TNF-alpha antagonist. These guidelines recommend reserving ustekinumab for use only in individuals with severe psoriasis for whom TNF-alpha antagonists have failed.
• The UK guidelines mention the possibility of combination therapy with methotrexate but indicate that the evidence for efficacy is weak.
• The NICE guidance states that there is a definite clinical benefit from a second biologic drug but that there is no robust evidence for choosing an order for use of biologics. NICE does not mention the option of combination treatment after failure to respond to a second biologic but suggests specialist care is needed.
• The German guidelines 29 provide criteria for modifying treatment if a patient has a PASI < 50 response or a DLQI score of greater than 5. The German recommendations for modifying treatment include increasing the dose, reducing dose intervals, adding a topical agent, adding another systemic therapy, or changing the drug.
ConClUSion
• Cost-effectiveness models of first-line biologics for moderate to severe plaque psoriasis either do not include subsequent treatment regimens or include only some of the regimens recommended in current treatment guidelines.
• Including treatment sequencing in future cost-effectiveness models may increase the usefulness of the estimates to health care decision makers.
